Search research articles
Contact Us
Filters
Showing results (101-110 of 162) with videos related to
Page
of 17
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
July 3, 2020
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis
Nathalie Van den Berghe, Aurélie Truffot, Miet Peeters, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 6, 2017
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Lieven Pouillon, Marc Ferrante, Gert Van Assche, et al.
Oncogene
|
August 3, 2004
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth
Khalid Bajou, Catherine Maillard, Maud Jost, et al.
Journal of Immunological Methods
|
August 19, 2009
Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes
Evelien Vandevenne, Sandy Van Buggenhout, Thomas Duvetter, et al.
Journal of Crohn'S & Colitis
|
March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study
Niels Vande Casteele, Filip Baert, Sumin Bian, et al.
Biosensors & Bioelectronics
|
April 2, 2022
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases
Henry Ordutowski, Francesco Dal Dosso, Wout De Wispelaere, et al.
Gut
|
April 12, 2015
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Filip Baert, Venkateswarlu Kondragunta, Steven Lockton, et al.
Journal of Crohn'S & Colitis
|
January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis
Iris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
Stroke
|
July 30, 2016
Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice
Frederik Denorme, Tine Wyseure, Miet Peeters, et al.
Scandinavian Journal of Gastroenterology
|
June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease
Thomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 162) with videos related to
Sort By:
Page
of 17
Journal of Pharmaceutical and Biomedical Analysis
|
July 3, 2020
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis
Nathalie Van den Berghe, Aurélie Truffot, Miet Peeters, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 6, 2017
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Lieven Pouillon, Marc Ferrante, Gert Van Assche, et al.
Oncogene
|
August 3, 2004
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth
Khalid Bajou, Catherine Maillard, Maud Jost, et al.
Journal of Immunological Methods
|
August 19, 2009
Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes
Evelien Vandevenne, Sandy Van Buggenhout, Thomas Duvetter, et al.
Journal of Crohn'S & Colitis
|
March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study
Niels Vande Casteele, Filip Baert, Sumin Bian, et al.
Biosensors & Bioelectronics
|
April 2, 2022
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases
Henry Ordutowski, Francesco Dal Dosso, Wout De Wispelaere, et al.
Gut
|
April 12, 2015
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Filip Baert, Venkateswarlu Kondragunta, Steven Lockton, et al.
Journal of Crohn'S & Colitis
|
January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis
Iris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
Stroke
|
July 30, 2016
Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice
Frederik Denorme, Tine Wyseure, Miet Peeters, et al.
Scandinavian Journal of Gastroenterology
|
June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease
Thomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Page
of 17